Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors | Zendy

Reid | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors

Author(s) -

Reid

Publication year - 2021

Publication title -

the journal of family practice

Language(s) - English

Resource type - Journals

eISSN - 1533-7294

DOI - 10.12788/jfp.0216

Subject(s) - medicine , guideline , intensive care medicine , diabetes mellitus , canagliflozin , kidney disease , type 2 diabetes mellitus , clinical trial , type 2 diabetes , heart failure , clinical practice , incidence (geometry) , empagliflozin , disease , endocrinology , physical therapy , pathology , physics , optics

At the end of the activity, participants will be able to:• Identify how heart failure (HF), chronic kidney disease (CKD), and type 2 diabetes mellitus (T2DM) and associated cardiovascular (CV) risks are interconnected.• Initiate guideline-recommended therapy to reduce CV risk in patients with HF, CKD, and/or T2DM.• Apply evidence for sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors) to clinical practice, based on recent and emerging trials.• Review evidence suggesting increased incidence and severity of COVID-19 infection in patients with diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research